China Inactivated Rabies Vaccine For Dog Related Injuries Manufacturer, Supplier, Factory

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. – a leading China-based manufacturer of human vaccines – produces the Inactivated Rabies Vaccine For Dog Related Injuries, a Vero cell‑propagated, freeze‑dried biological indicated for post‑exposure prophylaxis following canine bites, scratches, or mucous membrane contamination. With an annual manufacturing capacity of approximately 22 million doses and cumulative deliveries exceeding 100 million doses, this vaccine has been deployed across all 31 Chinese provinces and exported to more than 20 countries in South America, Central Asia, South Asia, Southeast Asia, and Africa. The conventional formulation (National Drug Approval No. S20073014) and the innovative serum‑free version (marketing application accepted under CXSS2500044) together offer a comprehensive solution for rabies prevention, a disease that remains 100% fatal once clinical signs appear.

Intended Use and Target Populations

The Inactivated Rabies Vaccine For Dog Related Injuries is specifically designed for active immunisation against rabies in persons of all ages who have sustained dog‑related injuries, including bites, scratches, or exposure of broken skin or mucous membranes to saliva or other potentially infectious materials. According to World Health Organization (WHO) exposure classification, the vaccine is indicated for Category II (minor scratches or abrasions without bleeding) and Category III (transdermal bites, lacerations, or mucous membrane contamination). For severe Category III exposures, simultaneous administration of rabies immunoglobulin (20 IU/kg) at a separate site is recommended to provide passive immunity while the vaccine elicits its active response. Healthcare facilities – including emergency rooms, community clinics, travel medicine centres, and veterinary occupational health units – represent primary points of use. The vaccine is also suitable for pre‑exposure immunisation in high‑risk occupational groups such as veterinarians, animal handlers, and laboratory personnel, though post‑exposure use remains its dominant application.

Formulation Variants and Comparative Parameters

Two technologically distinct versions of the Inactivated Rabies Vaccine For Dog Related Injuries are available to address diverse clinical, safety, and economic requirements. The conventional version utilises the rabies fixed virus aG strain propagated on Vero cells using standard culture media, with proven cost‑effectiveness over decades of use. The serum‑free version employs the PV‑2061 strain and eliminates bovine serum from every step – including cell revival, expansion, and virus cultivation – thereby reducing the risk of adventitious agent contamination, batch‑to‑batch variability, and serum‑related allergic reactions. Both are supplied as white porous lyophilisates that reconstitute to 1.0 mL clear solutions for intramuscular injection. The table below summarises their key distinctions:

Immunogenicity: Rapid and Durable Antibody Response

Effective post‑exposure prophylaxis hinges on the ability to generate neutralising antibodies before the virus reaches the central nervous system. Clinical evaluations of the Inactivated Rabies Vaccine For Dog Related Injuries have demonstrated a 100% seroconversion rate by day 14 post‑initiation, with antibody titres far exceeding the WHO‑recommended protective threshold of 0.5 IU/mL. The conventional version consistently delivers a mean potency of approximately 6.0 IU per dose – a substantial margin above the regulatory minimum. For the serum‑free formulation, geometric mean antibody concentrations (GMC) measured after the full course remain well above the protective level, and persistence studies confirm that protective titres are maintained for at least three months following the final dose. Such durable immunity is particularly valuable given the variable and often prolonged incubation period of rabies, which can extend from weeks to years in rare cases. The vaccine’s ability to elicit high‑avidity antibodies capable of cross‑neutralising diverse field strains has been repeatedly verified through stringent quality control assays performed on every production batch.

● Seroconversion kinetics: 100% by day 14, enabling early protection even before completion of the full course.

● Booster memory: The 5‑dose regimen induces robust anamnestic responses; the serum‑free version also accommodates the abbreviated 4‑dose schedule without loss of efficacy.

● Cross‑strain coverage: Antibodies raised against the vaccine strains effectively neutralise a broad range of wild‑type rabies viruses encountered globally.

Safety Profile and Post‑Marketing Surveillance

Safety is paramount in any biological product, and the Inactivated Rabies Vaccine For Dog Related Injuries benefits from an extensive post‑marketing safety database spanning over a hundred million administered doses. Adverse reactions are predominantly mild and transient, with local events (pain, erythema, swelling at the injection site) occurring in approximately 10–20% of recipients. Systemic reactions such as low‑grade fever, headache, dizziness, or myalgia are less common and typically resolve within 48 hours without specific treatment. No Grade 4 or above severe adverse events have been reported in association with this vaccine. The serum‑free formulation offers an enhanced safety margin by eliminating bovine serum, a known source of allergenic sensitisation and batch‑to‑batch variation. Furthermore, both versions are free from preservatives (including thiomersal), making them suitable for use in sensitive populations, including those with known allergies to vaccine additives. For patients with severe immunosuppression or acute febrile illness, vaccination should still proceed without delay following exposure, as the benefit of preventing rabies far outweighs any theoretical risk.

Recommended Dosing and Practical Administration

Adherence to the prescribed immunisation schedule is critical for achieving optimal protection with the Inactivated Rabies Vaccine For Dog Related Injuries. The standard Essen regimen consists of five intramuscular doses of 1.0 mL each, administered on days 0, 3, 7, 14, and 28 following exposure. The deltoid muscle is the preferred site in adults and older children, while the anterolateral thigh is recommended for infants. The serum‑free version additionally supports the WHO‑endorsed abbreviated 4‑dose schedule (days 0, 3, 7, and 14), which offers logistical advantages in resource‑limited settings or when patient compliance is a concern. The lyophilised vaccine must be reconstituted with the supplied diluent immediately before use; any unused reconstituted vaccine should be discarded after a few hours if not kept under refrigeration. Strict cold‑chain maintenance (2‑8°C, protected from light, never frozen) is mandatory throughout storage and transport. For patients previously vaccinated against rabies, a reduced booster regimen may be applied, but this should be determined on a case‑by‑case basis by a qualified healthcare professional.

Global Supply Reliability and Procurement Advantages

As the second‑largest rabies vaccine manufacturer worldwide and the largest private full‑industrial‑chain vaccine group in China, AIM Vaccine ensures a stable and scalable supply of the Inactivated Rabies Vaccine For Dog Related Injuries. The company operates four wholly‑owned licensed manufacturing subsidiaries, three dedicated vaccine research institutes, and four R&D centres, employing a total workforce of 1,501 professionals. Its products are distributed to over 2,800 district and county CDCs across China and exported to international markets including Pakistan, Kenya, Egypt, and numerous countries in Southeast Asia, Central Asia, and South America. Annual production capacity stands at approximately 22 million doses, with the flexibility to scale up in response to emergency tenders or outbreak situations. Procurement partners benefit from comprehensive support services, including regulatory dossier assistance, customised packaging options, and dedicated logistics coordination that maintains cold‑chain integrity from factory to destination. The company’s active participation in global exhibitions such as CPHI Europe, CPHI China, TIHE, VIF World 2025, and CPHI Middle East further underscores its commitment to long‑term international collaboration.

Manufacturing Excellence and Regulatory Oversight

Every batch of the Inactivated Rabies Vaccine For Dog Related Injuries is produced under a robust quality management system that undergoes rigorous scrutiny by China’s National Medical Products Administration (NMPA) and provincial regulatory bodies. The conventional version holds National Drug Approval Number S20073014, and its production lines most recently received GMP certification in December 2025, with annual surveillance inspections, follow‑up audits, and vaccine‑specific patrol inspections conducted routinely. The company is one of only two Chinese human vaccine manufacturers possessing P3 laboratory strategic resources, reflecting advanced biosafety and research capabilities. The serum‑free version has successfully completed Phase III clinical trials, demonstrating non‑inferior immunogenicity and superior safety compared to the conventional formulation; its marketing application has been accepted by the NMPA (Acceptance Notice No. CXSS2500044), positioning it to become the world’s first commercially available serum‑free rabies vaccine. Quality control protocols encompass comprehensive testing for potency (in vivo mouse challenge), sterility, endotoxin, residual DNA, and protein content, ensuring that each vial meets or exceeds both Chinese Pharmacopoeia and international standards.

Common Clinical and Procurement Queries

What is the earliest time to initiate vaccination after a dog bite?

Answer: Vaccination should begin as promptly as possible, ideally within 24 hours of exposure. However, even if more than 24 hours have passed, initiation remains strongly advised because the rabies incubation period is highly variable – ranging from weeks to several years. For Category III wounds, rabies immunoglobulin must be given concurrently with the first vaccine dose. There is no absolute upper time limit; as long as clinical symptoms have not appeared, post‑exposure prophylaxis is always indicated.

Can the conventional and serum‑free versions be interchanged during the same course?

Answer: Both versions are inactivated rabies vaccines that elicit similar neutralising antibody responses. Based on available data, sequential administration of different formulations or brands does not compromise immunogenicity. Nevertheless, for consistency and to minimise any potential variability, it is recommended to complete the full course with the same product whenever practically possible.

Are there special precautions for pregnant or nursing women?

Answer: Since rabies is invariably fatal once symptoms emerge, post‑exposure vaccination is not contraindicated during pregnancy or lactation. No adverse effects on pregnancy outcomes, foetal development, or nursing infants have been reported with inactivated rabies vaccines. Pregnant and lactating women should receive the vaccine when indicated, and the decision should be made in consultation with their healthcare provider.

How should the vaccine be stored and transported to maintain potency?

Answer: The lyophilised vaccine must be maintained at 2‑8°C throughout storage and transport, protected from light, and must never be frozen. During shipment, validated cold‑chain equipment with continuous temperature monitoring is mandatory. The diluent can be stored at ambient temperature or in the same cold chain, but the reconstituted vaccine should be used immediately or within a few hours if kept at 2‑8°C.

What is the cost difference between the two formulations and which is more economical?

Answer: The conventional version benefits from mature, large‑scale production and is more cost‑effective for mass immunisation programmes. The serum‑free version, while slightly more expensive due to its advanced culture process, offers added safety benefits (zero bovine serum) and is particularly suited for patients with allergy concerns or markets requiring highest purity. Both are competitively priced for international tenders and bulk procurement.

Commitment to Public Health Partnership

Choosing the right vaccine supplier involves more than product specifications – it requires a trusted partner with proven reliability, regulatory expertise, and a global footprint. AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. combines decades of manufacturing heritage, state‑of‑the‑art facilities, and a unwavering commitment to quality. Whether the Inactivated Rabies Vaccine For Dog Related Injuries is procured for emergency stockpiles, routine clinical use, or large‑scale campaigns, the company offers end‑to‑end support, including regulatory documentation, customs clearance, logistics planning, and post‑shipment technical assistance. By partnering with AIM Honor, healthcare systems and procurement agencies secure not only a superior vaccine but also a collaborative relationship dedicated to advancing global rabies elimination. For detailed quotations, sample requests, or customised packaging solutions, contact the international sales team directly.